Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations

Pharmacogenetics and Genomics

Volumn 21, Issue 4, 2011, Pages 179-184

  Wehland, Markus ^a   Bauer, Steffen ^a   Brakemeier, Susanne ^a   Burgwinkel, Philip ^a   Glander, Petra ^a   Kreutz, Reinhold ^a   Lorkowski, Christine ^a   Slowinski, Torsten ^a   Neumayer, Hans H ^a   Budde, Klemens ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

CYP3A5*3; Pharmacogenetics; Pharmacokinetics; Renal transplant; Twice daily tacrolimus

Indexed keywords

CYTOCHROME P450 3A5; TACROLIMUS;

ADULT; ARTICLE; DNA POLYMORPHISM; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG FORMULATION; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL;

EID: 79955473117     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32833ea085     Document Type: Article

References (22)

1. Silva HT Jr, Yang HC, Abouljoud M, Kuo PC,Wisemandle K, Bhattacharya P, et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007; 7:595-608. (Pubitemid 46376444)
2. Alloway R, Steinberg S, Khalil K, Gourishankar S, Miller J, Norman D, et al. Conversion of stable kidney transplant recipients from a twice daily prografbased regimen to a once daily modified release tacrolimus-based regimen. Transplant Proc 2005; 37:867-870. (Pubitemid 40590728)
3. Wlodarczyk Z, Squifflet JP, Ostrowski M, Rigotti P, Stefoni S, Citterio F, et al. Pharmacokinetics for once- versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, open-label trial. Am J Transplant 2009; 9:1-9.
4. De Jonge H, Naesens M, Kuypers DR. New insights into the pharmacokinetics and pharmacodynamics of the calcineurin inhibitors and mycophenolic acid: possible consequences for therapeutic drug monitoring in solid organ transplantation. Ther Drug Monit 2009; 31:416-435.
5. Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, et al. The human pregnane receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 2001; 11:555-572. (Pubitemid 32953582)
6. Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74:245-254. (Pubitemid 37083100)
7. Roy JN, Barama A, Poirer C,Vinet B, Roger M. Cyp3A4,Cyp3A5, andMDR-1 genetic influences on Tacrolimus pharmacokinetics in renal transplant recipients. Pharmacogenet Genomics 2006; 16:659-665. (Pubitemid 44223077)
8. Haufroid V, Mourad M, Van Kerckhove V, Wawrzyniak J, De Meyer M, Eddour DC, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and Tacrolimus dose requirements and trough blood levels in stable renal transplant recipients. Pharmacogenetics 2004; 14:147-154. (Pubitemid 38373108)
9. Press RR, Ploeger BA, den Hartigh J, van der Straaten T, van Pelt J, Danhof M, et al. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit 2009; 31:187-197.
10. Anglicheau D, Legendere C, Beaune P, Thervet E. Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. Pharmacogenomics 2007; 8:835-849. (Pubitemid 47288980)
11. Lee SJ, Usmani KA, Chanas B, Ghanayem B, Xi T, Hodgson E, et al. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 2003; 13:461-472. (Pubitemid 37034588)
12. Cross SA, Perry CM. Tacrolimus once-daily formulation: in the prophylaxis of transplant rejection in renal or liver allograft recipients. Drugs 2007; 67:1931-1943. (Pubitemid 47347405)
13. Lindemann G, Fritsche L, Schröter K, Schlaefer A, Budde K, Neumayer HH. Web-based patient record for hospitals - the design of TBase2-. In: Bruch HP, Kö ckerling F, Bouchard R, Schug-PaX C, editors. New aspects of high technology in medicine. Litosei - Rastignano, Bologna: Monduzzi Editore; 2000. pp. 409-414.
14. Johnston A, Jones K, Lee T, Stadler P, Holt DW. Tacrolimus external quality assessment, the European experience. Ther Drug Monit 1997; 19:555.
15. Kreutz R, Zürcher H, Kain S, Martus P, Offermann G, Beige J. The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. Pharmacogenetics 2004; 14:665-671. (Pubitemid 39411266)
16. Ihara H, Shinkuma D, Ichikawa Y, Nojima M, Nagano S, Ikoma F. Intra- and interindividual variation in the pharmacokinetics of tacrolimus (FK506) in kidney transplant recipients-importance of trough level as a practical indicator. Int J Urol 1995; 2:151-155.
17. Mourad M,Wallemacq P, De Meyer M, Brandt D, Van Kerkhove V, Malaise J, et al. The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function. Clin Chem Lab Med 2006; 44:1192-1198. (Pubitemid 44580800)
18. Zhang X, Liu ZH, Zheng JM, Chen ZH, Tang Z, Chen JS, et al. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clin Transplant 2005; 19:638-643. (Pubitemid 41341696)
19. Thelen K, Dressman JB. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol 2009; 61:541-558.
20. Berggren S, Gall C, Wollnitz N, Ekelund M, Karlbom U, Hoogstraate J, et al. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. Mol Pharm 2007; 4:252-257. (Pubitemid 46640601)
21. Canaparo R, Finnström N, Serpe L, Nordmark A, Muntoni E, Eandi M, et al. Expression of CYP3A isoforms and P-glycoprotein in human stomach, jejunum and ileum. Clin Exp Pharmacol Physiol 2007; 34:1138-1144. (Pubitemid 47416351)
22. Thörn M, Finnström N, Lundgren S, Rane A, Lö ö f L. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. Br J Clin Pharmacol 2005; 60:54-60. (Pubitemid 40942781)